PDR MEMBER LOGIN:
  • PDR Search

    Required field
  • Advertisement
  • Pneumovax 23
    (pneumococcal vaccine polyvalent)

    THERAPEUTIC CLASS

    Vaccine

    DEA CLASS

    RX

    INDICATIONS

    Active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine in persons ≥50 yrs of age and persons aged ≥2 yrs who are at increased risk for pneumococcal disease.

    ADULT DOSAGE

    Adults: 0.5mL dose SQ/IM into the deltoid muscle or lateral mid-thigh.

    PEDIATRIC DOSAGE

    Pediatrics: ≥2 Yrs: 0.5mL dose SQ/IM into the deltoid muscle or lateral mid-thigh.

    ADMINISTRATION

    IM/SQ route. Inject into the deltoid muscle or lateral mid-thigh. Do not mix with other vaccines in the same syringe or vial. Refer to PI for further preparation, administration, and revaccination instructions.

    HOW SUPPLIED

    Inj: 0.5mL [prefilled syringe, single-dose vial, multidose vial]

    WARNINGS/PRECAUTIONS

    Do not inject intravascularly or intradermally. Defer vaccination in patients with moderate or severe acute illness. Caution with severely compromised cardiovascular (CV) and/or pulmonary function in whom a systemic reaction would pose a significant risk. Does not replace the need for antibiotic prophylaxis (eg, penicillin) against pneumococcal infection; antibiotic prophylaxis should not be discontinued after vaccination in patients who require antibiotic prophylaxis. Response to vaccine may be diminished in immunocompromised individuals. May not be effective in preventing pneumococcal meningitis in patients with chronic CSF leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures. Will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. Caution in elderly.

    ADVERSE REACTIONS

    Local inj-site reactions (eg, pain, soreness, tenderness, swelling, induration, erythema), asthenia, fatigue, myalgia, headache.

    DRUG INTERACTIONS

    Persons receiving immunosuppressive therapies may have a diminished immune response to the vaccine. Reduced immune response to zoster vaccine live reported; consider separation of vaccinations by at least 4 weeks.

    PREGNANCY AND LACTATION

    Category C, caution in nursing.

    MECHANISM OF ACTION

    Vaccine; induces antibodies that enhance opsonization, phagocytosis, and killing of pneumococci by leukocytes and other phagocytic cells.

    ASSESSMENT

    Assess for moderate/severe acute illness, severely compromised CV and/or pulmonary function, chronic CSF leakage, vaccination history, history of anaphylactic/anaphylactoid or severe allergic reaction to any component of the vaccine, immunocompromised conditions, pregnancy/nursing status, and for possible drug interactions.

    MONITORING

    Monitor for hypersensitivity reactions and other adverse reactions.

    PATIENT COUNSELING

    Inform of potential benefits/risks of vaccination. Inform that the vaccine may not offer 100% protection from pneumococcal infection. Instruct to report any serious adverse reactions to physician.

    STORAGE

    2-8°C (36-46°F).